IQV
IQVIA HOLDINGS INC.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$265.88
−0.38%Year over year
Reported trailing growth
- Revenue
- +8.2%
- EBITDA
- +5.3%
- EBIT
- +5.8%
- EPS
- +16.5%
- Free cash flow
- +30.0%
- Operating cash flow
- +7.7%
Forward estimates
Based on analyst estimates
- Revenue
- +6.9%
- EBITDA
- +31.7%
- EPS
- +72.0%
Three-year CAGR
- Revenue
- +4.2%
- EBITDA
- +0.3%
- EBIT
- +6.6%
- Net income
- +7.6%
- EPS
- +10.8%
- Free cash flow
- +8.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026